DOCSLIB.ORG

Advances in Cancer Nanotechnology: Nci Alliance 2005-2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advances in Cancer Nanotechnology: Nci Alliance 2005-2010 ADVANCES IN CANCER NANOTECHNOLOGY: NCI ALLIANCE 2005-2010 The NCI Office of Cancer Nanotechnology Research/ Center for Strategic Scientific Initiatives National Cancer Institute/ NIH NOVEMBER 2010 NCI Alliance for Nanotechnology in Cancer NCI Alliance for Nanotechnology in Cancer TABLE OF CONTENTS ABOUT THE ALLIANCE FOR NANOTECHNOLOGY IN CANCER ............................................ 3 SCIENTIFIC FOCUS ............................................................................................................................................................... 4 PROGRAM OPERATION AND STRUCTURE .......................................................................... 7 PROGRAM OPERATION ........................................................................................................................................................... 7 Office of Cancer Nanotechnology Research ....................................................................................................................... 8 PROGRAM INFRASTRUCTURE ..................................................................................................................................................... 8 Centers of Cancer Nanotechnology Excellence ................................................................................................................. 9 Cancer Nanotechnology Platform Partnerships .............................................................................................................. 11 Multidisciplinary Research Training and Team Development ....................................................................................... 16 Nanotechnology Characterization Laboratory ................................................................................................................ 17 SCIENTIFIC ACHIEVEMENTS ............................................................................................. 19 RECOGNITION AWARDS .......................................................................................................................................................... 19 SCIENTIFIC HIGHLIGHTS ......................................................................................................................................................... 21 MOLECULAR IMAGING AND THE EARLY DETECTION OF CANCER ................................................................................................. 21 Magneto-Nano Protein Chip and Multiplex Sorter for Monitoring Tumors Antigens .................................................. 21 Biobarcode Assay for Measuring Undetectable Levels of Prostate Specific Antigen ....................................................... 25 IN VIVO IMAGING .................................................................................................................................................................... 27 Tumor Cell Imaging Using Magnetic Nanoparticles ..................................................................................................... 27 Near-Infrared Fluorescent Nanoparticles for Targeted Optical Imaging and Drug Delivery......................................... 28 REPORTERS OF THERAPEUTIC EFFICACY .................................................................................................................................. 30 Targeted Nanosystems for Therapy and Imaging ........................................................................................................... 30 Implantable Device for Continuous Cancer Monitoring................................................................................................. 32 Blood Protein Profiling of Glioblastoma Patients: Addressing the Question of Patient Response to Avastin® Therapy 32 MULTIFUNCTIONAL THERAPEUTICS ......................................................................................................................................... 34 Nanotherapeutic Strategy for Multidrug Resistant Tumors .......................................................................................... 34 Dendrimer Nanoparticles for Cancer Diagnosis and Treatment .................................................................................... 35 Targeting Central Nervous System Tumors with Imaging Nanoprobes ........................................................................ 36 Multifunctional Nanoparticles for Early Detection of Pancreatic Cancer ...................................................................... 37 PREVENTION AND CONTROL OF CANCER .................................................................................................................................. 38 PRINT® Technology for Cancer Therapy and Imaging .................................................................................................. 38 Rapid Isolation and Detection of Cell Free Circulating DNA Biomarkers and Nanoparticles Directly from Whole Blood .............................................................................................................................................................. 39 RESEARCH ENABLERS ............................................................................................................................................................. 40 Deconstructing Directional Cell Motility in Metastasis through Nanopatterning ........................................................ 40 Cancer Antibody Functionalized Gold Nanopyramids ................................................................................................... 41 Diagnostic Nanoarrays ................................................................................................................................................... 42 PUBLICATION STATISTICS ....................................................................................................................................................... 42 Selected Publications with High Impact Factor .............................................................................................................. 43 DEVELOPMENT OF TRANSLATIONAL TECHNOLOGIES .................................................... 45 MOVING TO THE CLINIC .......................................................................................................................................................... 45 Cyclodextrin for Delivering Camptothecin and siRNA .................................................................................................. 45 New PET Imaging Agent ............................................................................................................................................... 47 Novel Nanotechnology-Based MRI Contrast Agent ....................................................................................................... 48 Superparamagnetic Nanoparticles for Detection Lymph Node Metastases .................................................................... 49 Polymeric Nanoparticles for Targeted Anticancer Drug Delivery ................................................................................. 50 NCI Alliance for Nanotechnology in Cancer Carbon Nanotube X-ray Source ...................................................................................................................................... 52 Surface Enhanced Raman Spectrometry Gold-Based Nanoparticles for Colorectal Cancer Detection ............................ 53 Chemically Engineered Adenovirus Nanoparticles to Improve Immune Gene Therapy in Chronic Lymphocytic Leukemia ................................................................................................................................................................... 54 NANOTECHNOLOGY CHARACTERIZATION LABORATORY ............................................................................................................. 55 TECHNOLOGY TRANSFER AND COMMERCIALIZATION .................................................... 59 ANC INDUSTRIAL PARTNERSHIPS AND COMPANY PROFILES ...................................................................................................... 59 SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM .................................................................................................... 67 BIOINFORMATICS AND DATA SHARING ........................................................................... 71 CONNECTIVITY WITH CABIG® .................................................................................................................................................. 71 CANANOLAB ........................................................................................................................................................................... 71 Nanotechnology Data Sharing Standards ....................................................................................................................... 72 MEETINGS ......................................................................................................................... 73 ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF CANCER RESEARCH ............................................................................... 73 ANNUAL ANC INVESTIGATORS MEETINGS ................................................................................................................................ 74 NCI STRATEGIC WORKSHOPS .................................................................................................................................................. 75 BEST PRACTICES IN NANOTECHNOLOGY
Load more

Recommended publications
  • The Case for Convergence [Entire Talk]
    Stanford eCorner The Case for Convergence [Entire Talk] Joseph DeSimone, Carbon 01-07-2020 URL: https://ecorner.stanford.edu/videos/the-case-for-convergence-entire-talk/ Joe DeSimone is the founder and executive chairman of Carbon, a global company that is driving the evolution of 3D printing from a prototyping tool into a scalable manufacturing technology. As a professor at the University of North Carolina, DeSimone made scientific breakthroughs in areas including green chemistry, medical devices, and nanotechnology, also co-founding several companies based on his research. In 2016 President Obama awarded him the National Medal of Technology and Innovation, the highest honor in the U.S. for achievement and leadership in advancing technological progress. In this talk, he explores how diverse teams, perspectives and specialties can drive innovations in both technologies and business models. Transcript Presenter Who you are, defines how you built.. 00:00:08,890 - We're welcoming back, Joe.. 00:00:13,330 Who was here, of just, almost four years ago in 2016.. He co-founded Carbon three years before that.. Previously, he was professor at university of North Carolina, but while you were there, you were also, you do these scientific breakthroughs like I mentioned, in co- founding several companies, all before launching Carbon.. So can you share a little bit more about that path and how you balance those two? - Well, sure.. 00:00:40,840 It's great to connect with a Dukie here, as a Tar Heel but, in fact my first PhD student, Valerie Ashby is now Dean of Trinity college at Duke university.
    [Show full text]
  • Examining the Technology for a Sustainable Environment Grant Program
    Examining the Technology for a Sustainable Environment Grant Program An Interactive Qualifying Project Report Submitted to the Faculty of WORCESTER POLYTECHNIC INSTIUTE In partial fulfillment of the requirements for the Degree of Bachelor of Science Submitted to: Professor James Demetry Professor Joseph Petruccelli Worcester Polytechnic Institute: Washington, D.C. Project Center By: Eddie Diaz _____________________ Melissa Hinton _____________________ Mark Stevenson _____________________ December 13, 2004 In Cooperation with the Environmental Protection Agency Diana Bauer, Ph.D April Richards, PE National Center of National Center of Environmental Research Environmental Research Environmental Protection Environmental Protection Agency Agency Washington, DC 20005 Washington, DC 20005 This report is submitted in partial fulfillment of the degree requirements of Worcester Polytechnic Institute. The views and opinions expressed herein are those of the authors and do not necessarily reflect the positions or opinions of the Environmental Protection Agency or Worcester Polytechnic Institute. Abstract This project was performed with the support of the Environmental Protection Agency and involved the examination of the Technology for a Sustainable Environment (TSE) grants program. We selected ten researchers funded by the TSE program, interviewed them, and reviewed their research in terms of qualitative and quantitative academic, industrial, and potential environmental impacts. For each of the ten researchers, we wove this information together
    [Show full text]
  • May 26, 2010 Sincerely, Cynthia J. Burrows Distinguished Professor Chair, 2010 COV For
    Cynthia J. Burrows Phone: (801) 585-7290 Distinguished Professor Fax: (801) 585-0024 of Chemistry Email: [email protected] May 26, 2010 Dr. Iain M. Johnstone Department of Statistics Stanford University 450 Serra Mall Stanford, CA 94305-2070 Dear Iain, Enclosed please find the report of the Committee of Visitors to the Chemistry Division, which met from May 3-5, 2010. The report includes: • The general conclusions and recommendations of the committee • A summary of the specific findings of the COV concerning the review process, the outcomes of CHE’s investments, and the response of CHE to the 2007 COV report • The membership of the 2010 COV • The charge to the COV from Dr. Ed Seidel • Individual reports from seven subpanels • Responses to template questions The COV concluded that outstanding science is being funded through this program, and that the scientific staff of CHE are demonstrating excellence in management of this diverse portfolio. On behalf of the COV, Sincerely, Cynthia J. Burrows Distinguished Professor Chair, 2010 COV for CHE Department of Chemistry 315 South 1400 East Salt Lake City, Utah 84112 Report of the Committee of Visitors Division of Chemistry National Science Foundation May 3-5, 2010 I. Background The Committee of Visitors for the Division of Chemistry (CHE) met for three days to review the activities of the Division during the three-year period 2007-2009. The original meeting dates of February 9-11, 2010 were rescheduled due to a snowstorm in the Washington, DC area. Nearly 80% of the original COV members were able to attend the rescheduled meeting, but additional members were sought to cover a diversity of scientific, geographic, institutional and demographic characteristics.
    [Show full text]
  • THE ASSIST CENTER NC State Is Now the Nation’S Only University Leading Two Active NSF Engineering Research Centers
    FALL/WINTER 2012 THE ASSIST CENTER NC State is now the nation’s only university leading two active NSF Engineering Research Centers RISING FACULTY STARS PROBLEM-SOLVING SENIOR PROJECTS ADVICE FROM AMELIA Katharine Stinson’s barrier-breaking engineering career Just one year and a whopping 48 credit hours later, she started in 1932 on the dusty runway of her hometown marched back to NC State. She graduated in 1941 with a airstrip. BS in mechanical engineering with an aeronautics option, becoming the first woman to leave the university with an Legendary flyer Amelia Earhart (above right) had engineering degree. touched down at the old Raleigh Municipal Airport, and the 15-year-old Stinson stole a moment with her idol to Stinson spent the next 32 years with the US Civil share her dream of becoming a pilot. But pilots didn’t Aeronautics Administration (now the Federal Aviation make much money in those days, and Earhart suggested Administration) making key contributions to aircraft another occupation. safety. She even served on an advisory committee under President Lyndon Johnson. “Don’t become a pilot, become an engineer,” Stinson recalled her saying. But Stinson never forgot her NC State roots, and the university never forgot her. She became the first woman Stinson (above left) took the advice. But when she to serve on the Alumni Association Board of Directors and applied to NC State a few years later, she hit a roadblock: earn recognition as a Distinguished Engineering Alumna. Women weren’t allowed to study engineering at the university. To give other women similar opportunities, she established the Katharine Stinson Scholarships for Stinson persisted, convincing the dean of engineering to Women in Engineering in 1987.
    [Show full text]
  • Optimization of Surface Display of DENV2 E Protein on a Nanoparticle to Induce Virus Specific Neutralizing Antibody Responses Jason E
    Optimization of Surface Display of DENV2 E Protein on a Nanoparticle to Induce Virus Specific Neutralizing Antibody Responses Jason E. Coffman,† Stefan W. Metz,‡ Alex Brackbill,§ Molly Paul,∥ Michael J. Miley,§ Joseph DeSimone,†,∥,⊥ J. Christopher Luft,# Aravinda de Silva,‡ and Shaomin Tian*,‡ † Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, North Carolina 27607, United States ‡ § ∥ ⊥ Department of Microbiology and Immunology, Department of Pharmacology, Department of Chemistry, Lineberger # Comprehensive Center, and Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States ABSTRACT: The dengue virus (DENV) causes over 350 million infections, resulting in ∼25,000 deaths per year globally. An effective dengue vaccine requires generation of strong and balanced neutralizing antibodies against all four antigenically distinct serotypes of DENV. The leading live- attenuated tetravalent dengue virus vaccine platform has shown partial efficacy, with an unbalanced response across the four serotypes in clinical trials. DENV subunit vaccine platforms are being developed because they provide a strong safety profile and are expected to avoid the unbalanced immunization issues associated with live multivalent vaccines. Subunit vaccines often lack immunogenicity, requiring either a particulate or adjuvanted formulation. Particulate formulations adsorbing monomeric DENV-E antigen to the particle surface incite a strong immune response, but have no control of antigen presentation. Highly neutralizing epitopes are displayed by DENV-E quaternary structures. To control the display of DENV-E and produce quaternary structures, particulate formulations that covalently attach DENV-E to the particle surface are needed. Here we develop a surface attached DENV2-E particulate formulation, as well as analysis tools, using PEG hydrogel nanoparticles created with particle replication in nonwetting templates (PRINT) technology.
    [Show full text]
  • Engineering Semiconductor Nanocrystals For
    ENGINEERING SEMICONDUCTOR NANOCRYSTALS FOR MOLECULAR, CELLULAR, AND IN VIVO IMAGING A Dissertation Presented to The Academic Faculty By Andrew Michael Smith In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Department of Biomedical Engineering Georgia Institute of Technology December, 2008 Copyright © 2008 by Andrew Michael Smith ENGINEERING SEMICONDUCTOR NANOCRYSTALS FOR MOLECULAR, CELLULAR, AND IN VIVO IMAGING Approved by: Dr. Shuming Nie, Advisor Dr. Zhong L. Wang School of Biomedical Engineering School of Materials Science and Georgia Institute of Technology Engineering Georgia Institute of Technology Dr. Gang Bao School of Biomedical Engineering Dr. Lily Yang Georgia Institute of Technology Department of Surgery Emory University Dr. Niren Murthy School of Biomedical Engineering Georgia Institute of Technology Date approved: October 16, 2008 ACKNOWLEDGEMENTS I dedicate this thesis to my parents, Marge and Winston, and my brother Edward, who have always supported me. I owe to them my values, work ethic, and aspiration to pursue a life of continuous learning. I thank my beautiful and incredibly intelligent girlfriend Mia for being compassionate and patient through the completion of my degree. I am grateful for guidance and inspiration from my friends, family members, and teachers, especially George Petsch, France Dorman, Mark Sommerville, James Powers, Athanassios Sambanis, Joseph Berglund, Schiue-Cheng Tang, Jonathan Beech, and James Mickens. I also thank Matthew Rhyner, Aaron Mohs, Michael Mancini, and Brad Kairdolf, who have taken part in the collaborative efforts of this thesis. Finally, I thank my research advisor, Shuming Nie, an inspiring leader and a brilliant mind who has given me tremendous opportunities over the past six years to learn a broad range of scientific disciplines, the encouragement to work harder than I have ever thought possible, and a vision for my future and the future of science and innovation.
    [Show full text]
  • Table of Contents University of Rochester Department of Chemistry 404 Hutchison Hall RC Box 270216 Chemistry Department Faculty and Staff Rochester, NY 14627-0216 3
    CONTACT ADDRESS Table of Contents University of Rochester Department of Chemistry 404 Hutchison Hall RC Box 270216 Chemistry Department Faculty and Staff Rochester, NY 14627-0216 3 PHONE 4 Letter from the Chair (585) 275-4231 6 Donors to the Chemistry Department EMAIL 10 Alumni News [email protected] Esther M. Conwell receives National Medal of Science WEBSITE 14 http://www.chem.rochester.edu 16 A Celebration in Honor of Richard Eisenberg 18 Department Mourns the Loss of Jack Kampmeier CREDITS 20 Xiaowei Zhuang receives the 2010 Magomedov- EDITOR Shcherbinina Award Lory Hedges 21 Joseph DeSimone receives for 2011 Harrison Howe LAYOUT & DESIGN EDITOR John Bertola (B.A. ’09, M.S. ’10W) Award Lory Hedges 22 Chemistry Welcomes Michael Neidig REVIEWING EDITORS Kirstin Campbell 23 New Organic Chemistry Lab Lynda McGarry Terrell Samoriski 24 The 2011 Biological Chemistry Cluster Retreat Barb Snaith 26 Student Awards and Accolades COVER ART AND LOGOS Faculty News Breanna Eng (’13) 28 Sheridan Vincent 60 Faculty Publications WRITING CONTRIBUTIONS 66 Commencement 2011 Department Faculty Lory Hedges 68 Commencement Awards Breanna Eng (’13) Terri Clark 69 Postdoctoral Fellows and Research Associates Select Alumni 70 Seminars and Colloquia PHOTOGRAPHS UR Communications 74 Staff News National Science & Technology Departmental Funds Medals Foundation 79 John Bertola (B.A. ’09, M.S. ’10W) 80 Alumni Update Form Karen Chiang Ria Casartelli Sheridan Vincent Thomas Krugh 1 2 Faculty and Staff FACULTY RESEARCH PROFESSORS BUSINESS OFFICE Esther M. Conwell Anna Kuitems PROFESSORS OF Samir Farid Randi Shaw CHEMISTRY Diane Visiko Robert K. Boeckman, Jr. SENIOR SCIENTISTS Doris Wheeler Kara L.
    [Show full text]
  • NIH Public Access Author Manuscript Acc Chem Res
    NIH Public Access Author Manuscript Acc Chem Res. Author manuscript; available in PMC 2014 September 08. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Acc Chem Res. 2011 October 18; 44(10): 990–998. doi:10.1021/ar2000315. PRINT: A Novel Platform Toward Shape and Size Specific Nanoparticle Theranostics JILLIAN L. PERRY, KEVIN P. HERLIHY, MARY E. NAPIER, and JOSEPH M. DESIMONE Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States CONSPECTUS Nanotheranostics represents the next generation of medicine, fusing nanotechnology, therapeutics, and diagnostics. By integrating therapeutic and imaging agents into one nanoparticle, this new treatment strategy has the potential not only to detect and diagnose disease but also to treat and monitor the therapeutic response. This capability could have a profound impact in both the research setting as well as in a clinical setting. In the research setting, such a capability will allow research scientists to rapidly assess the performance of new therapeutics in an effort to iterate their designs for increased therapeutic index and efficacy. In the clinical setting, theranostics offers the ability to determine whether patients enrolling in clinical trials are responding, or are expected to respond, to a given therapy based on the hypothesis associated with the biological mechanisms being tested. If not, patients can be more quickly removed from the clinical trial and shifted to other therapeutic options. To be effective, these theranostic agents must be highly site specific. Optimally, they will carry relevant cargo, demonstrate controlled release of that cargo, and include imaging probes with a high signal-to-noise ratio.
    [Show full text]
  • Characterization of Phase Equilibrium Associated with Heterogeneous Polymerizations in Supercritical Carbon Dioxide
    ABSTRACT KENNEDY, KAREN ALYCE. Characterization of Phase Equilibrium Associated with Heterogeneous Polymerizations in Supercritical Carbon Dioxide. (Under the direction of Dr. George W. Roberts and Dr. Joseph M. DeSimone) This thesis details research to understand the phase equilibrium associated with heterogeneous polymerizations in supercritical carbon dioxide (scCO2), particularly the polymerization of vinylidene fluoride (VF2) in scCO2. Knowledge of the equilibrium between the supercritical fluid and polymer phases may be applied to understanding the mechanisms involved in heterogeneous polymerizations in scCO2. Several experimental systems were developed and/or utilized for measuring the phase equilibrium. These included a system for measuring the swelling of solid polymer particles in the presence of scCO2, a system for measuring the mass sorption and diffusion of supercritical fluids into the polymer phase, and a system for measuring the partitioning of reactant species between the polymer and supercritical fluid phases. The sorption and swelling of poly(vinylidene fluoride) (PVDF) was measured at conditions similar to those of the polymerizations. The Sanchez- Lacombe equation of state was applied to modeling the binary and ternary phase equilibria for the VF2-CO2-PVDF system. Carbon dioxide exhibits a favorable interaction with PVDF that is enhanced at increasing fluid densities. Additionally, the monomer exhibits a favorable interaction with PVDF that improves the mass sorption into the polymer phase and expands the tunability of the fluid to change the polymer properties. The impact of the phase equilibrium on the precipitation polymerization of vinylidene fluoride in scCO2 is discussed. The bimodal molecular weight distribution of PVDF synthesized in CO2 could be due, in part, to the sorption of VF2 into the polymer phase and the plasticization of the polymer to facilitate propagation of the polymer chains to high molecular weights within the polymer particles.
    [Show full text]
  • Andrew-Smith-Cv-1718.Pdf
    Andrew M. Smith Department of Bioengineering, University of Illinois at Urbana-Champaign 3114 Micro and Nanotechnology Laboratory, 208 N Wright St, M/C 249, Urbana, IL 61801 [Tel]: (404) 642-1303, [Fax]: (217) 265-0246, [Email]: [email protected] EDUCATION 2008 Ph.D. Bioengineering Georgia Institute of Technology, Atlanta, GA 2002 B.S. Chemistry Georgia Institute of Technology, Atlanta, GA RESEARCH POSITIONS AND EMPLOYMENT 2017- AssistAnt Professor of TeChnology Entrepreneurship University of Illinois at Urbana-Champaign 2017- AssistAnt Professor And AssoCiAte Course DireCtor Carle Illinois College of Medicine 2016- ReseArCh Theme FACulty of OmiCs NAnoteChnology for CAnCer PreCision MediCine (ONC-PM) Carl R. Woese Institute for Genomic Biology (IGB) University of Illinois at Urbana-Champaign 2016- AssoCiAte HeAd of UndergrAduAte ProgrAms, DepArtment of Bioengineering (Interim 2016-2017) University of Illinois at Urbana-Champaign 2013- Full-Time Resident FaCulty of the MiCro And Nanotechnology Laboratory (MNTL) University of Illinois at Urbana-Champaign 2013- AffiliAte FACulty of MAterials Science and Engineering University of Illinois at Urbana-Champaign 2012- AssistAnt Professor of Bioengineering University of Illinois at Urbana-Champaign 2010-2012 NIH/NCI K99/R00 PostdoCtorAl Fellow in CanCer NanoteChnology Emory University, Atlanta, GA and Yeshiva University Albert Einstein College of Medicine, Bronx, NY Research mentor: Professor Shuming Nie, Collaborator John Condeelis 2008-2012 Distinguished CCNE PostdoCtorAl Fellow Emory University
    [Show full text]
  • Senior Editors Editorial Advisory Board Editor-In
    EDITOR-IN-CHIEF: CAROLYN R. BERTOZZI Professor of Chemistry and (by courtesy) Chemical and Systems Biology Department of Chemistry Stanford University Keck Science Building Stanford, California 94305 E-mail [email protected] MANAGING EDITOR Miranda Paley (202) 872-7882 [email protected] SENIOR EDITORS Christopher J. Chang Benjamin G. Davis University of California, Berkeley University of Oxford Monica Olvera de la Cruz David A. Tirrell Northwestern University California Institute of Technology Dongyuan Zhao Fudan University EDITORIAL ADVISORY BOARD Adah Almutairi Laura Gagliardi Kimberly A. Prather University of California, San Diego University of Minnesota University of California, San Diego Frances H. Arnold Giulia Galli Nora Radu California Institute of Technology The University of Chicago Dupont Alán Aspuru-Guzik Justin P. Gallivan A. R. Ravishankara Harvard University Emory University Colorado State University Ryan C. Bailey Lila M. Gierasch John Reynolds University of Illinois at Urbana Champaign University of Massachusetts, Amherst Georgia Institute of Technology Vikram Bajaj Jeff Gildersleeve Gavin Sacks GoogleX NIH Cornell University Hagan Bayley Rainer Haag Elena Shevchenko University of Oxford Freie Universität Berlin Argonne National Lab Chemistry Research Laboratory Itaru Hamachi Kevan M. Shokat Phil S. Baran Kyoto University University of California, San Francisco The Scripps Research Institute Clifton E. Barry, III John F. Hartwig Shannon S. Stahl National Institutes of Health University of California, Berkeley University of Wisconsin, Madison James D. Batteas Chuan He James Stevens Texas A&M University University of Chicago Dow Donna G. Blackmond Taeghwan Hyeon Samuel I. Stupp The Scripps Research Institute Seoul National University Northwestern University Steven G. Boxer Jim Inglese Shana J.
    [Show full text]
  • Ucrf Annual Report FINAL.Qxp
    ucrf annual report FINAL.qxp 5/21/2008 12:02 PM Page 3 cancerLines University Cancer Research Fund A special 2007-2008 report from UNC Health Care and UNC Lineberger Comprehensive Cancer Center Two National Cancer Accelerating the Fight Against Cancer in NC Experts Serve on In 2008 an estimated 40,420 North Carolinians will be programs. These strategies include bringing genetics and Cancer Research Fund diagnosed with cancer. This disease is the number one cause genomics to clinical care, promoting drug discovery and clinical of death in our state and will claim more than 17,000 lives trials, assessing cancer in our communities, applying innovations Committee this year. North Carolina is swimming against a to bring world-class cancer care to the state, and developing a demographic tide of growth and aging that will bring more unique and comprehensive study of cancer survivors. The fund The Cancer Research Fund Committee, than 80,000 new cancer cases in 2030. Research that leads has also completed its governance structure, initiated a strategic led by UNC President Erskine Bowles, to more effective treatment, better prevention, and improved planning process, conducted listening sessions around the state, has been meeting quarterly to oversee screening is critical to answering this challenge for our and instituted a collaboration with East Carolina University. The and approve expenditures of the UCRF children and our children's children. fund is establishing an independent evaluation process and and prioritize and guide its projects. In July 2007, the NC General Assembly established the beginning to develop outreach networks to speed clinical and Other UNC committee members University Cancer Research Fund (UCRF) to dramatically other innovations to communities across the state.
    [Show full text]